Organon Correlations
OGN Stock | USD 15.74 0.44 2.72% |
The current 90-days correlation between Organon and Biogen Inc is 0.09 (i.e., Significant diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organon Co moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Organon |
Moving together with Organon Stock
0.76 | EQ | Equillium | PairCorr |
0.82 | ME | 23Andme Holding | PairCorr |
0.79 | VALN | Valneva SE ADR | PairCorr |
0.62 | DNTH | Dianthus Therapeutics | PairCorr |
0.72 | DRRX | Durect | PairCorr |
0.73 | DTIL | Precision BioSciences | PairCorr |
0.71 | VIGL | Vigil Neuroscience | PairCorr |
0.7 | VINC | Vincerx Pharma | PairCorr |
0.72 | VKTX | Viking Therapeutics | PairCorr |
0.81 | VRCA | Verrica Pharmaceuticals | PairCorr |
0.63 | VTGN | VistaGen Therapeutics | PairCorr |
Moving against Organon Stock
0.79 | VCEL | Vericel Corp Ord | PairCorr |
0.72 | DVAX | Dynavax Technologies | PairCorr |
0.68 | VCYT | Veracyte Potential Growth | PairCorr |
0.64 | DYAI | Dyadic International | PairCorr |
0.53 | CDIOW | Cardio Diagnostics | PairCorr |
0.46 | DRTS | Alpha Tau Medical | PairCorr |
0.44 | DMAC | DiaMedica Therapeutics | PairCorr |
0.39 | DSGN | Design Therapeutics | PairCorr |
0.38 | SRZNW | Surrozen Warrant | PairCorr |
0.35 | SABSW | SAB Biotherapeutics | PairCorr |
0.35 | KTTAW | Pasithea Therapeutics | PairCorr |
0.62 | VTRS | Viatris | PairCorr |
0.54 | VRNA | Verona Pharma PLC | PairCorr |
0.53 | ELUT | Elutia Inc | PairCorr |
0.49 | ENSC | Ensysce Biosciences Upward Rally | PairCorr |
0.45 | ELDN | Eledon Pharmaceuticals | PairCorr |
0.43 | VSTM | Verastem | PairCorr |
0.43 | ELTX | Elicio Therapeutics | PairCorr |
0.36 | VTVT | vTv Therapeutics | PairCorr |
0.31 | VYNE | Vyne Therapeutics | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Organon Stock performing well and Organon Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Organon's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
JNJ | 0.74 | (0.14) | 0.00 | 2.53 | 0.00 | 1.70 | 4.50 | |||
BMY | 1.22 | 0.13 | 0.07 | (2.40) | 1.39 | 2.51 | 14.38 | |||
ABBV | 1.17 | (0.16) | 0.00 | (0.86) | 0.00 | 2.37 | 18.93 | |||
LLY | 1.49 | (0.36) | 0.00 | (1.52) | 0.00 | 3.25 | 11.14 | |||
PFE | 1.09 | (0.13) | 0.00 | 1.59 | 0.00 | 2.03 | 6.72 | |||
AMGN | 1.06 | (0.26) | 0.00 | (0.49) | 0.00 | 1.60 | 8.60 | |||
MRK | 1.00 | (0.17) | 0.00 | (0.68) | 0.00 | 1.74 | 5.17 | |||
GILD | 1.01 | 0.13 | 0.07 | 0.56 | 1.35 | 1.94 | 10.79 | |||
SNY | 1.02 | (0.12) | 0.00 | (4.09) | 0.00 | 2.16 | 10.59 | |||
AZN | 1.07 | (0.23) | 0.00 | 0.51 | 0.00 | 1.68 | 8.50 |
Organon Corporate Management
Susan ONeal | Chief Officer | Profile | |
Rebecca Edwards | Chief Officer | Profile | |
Rachel Stahler | Executive Officer | Profile | |
Susanne Fiedler | Executive Officer | Profile | |
Daniel Karp | Executive Development | Profile |